Provided by Tiger Trade Technology Pte. Ltd.

NEWAMSTERDAM PHARMA CO NV

25.59
+0.67002.69%
Post-market: 25.590.00000.00%16:15 EDT
Volume:979.90K
Turnover:24.94M
Market Cap:3.06B
PE:-11.93
High:26.01
Open:25.15
Low:25.00
Close:24.92
52wk High:42.21
52wk Low:23.05
Shares:119.54M
Float Shares:92.51M
Volume Ratio:1.05
T/O Rate:1.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1442
EPS(LYR):-1.7211
ROE:-36.81%
ROA:-20.11%
PB:4.84
PE(LYR):-14.87

Loading ...

Stock Track | NewAmsterdam Pharma Soars 5.31% Intraday on Guggenheim's Buy Rating

Stock Track
·
May 08

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 08

Guggenheim Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)

TIPRANKS
·
May 08

NewAmsterdam Pharma Company NV reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 08

NewAmsterdam Pharma Q1 net loss widens to USD 48.4 million

Reuters
·
May 07

Press Release: NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

Dow Jones
·
May 07

NewAmsterdam Pharma grants 50,400 inducement share options at $28.43 per share

Reuters
·
May 02

NewAmsterdam Pharma Chief Accounting Officer Louise Kooij to depart Aug. 31

Reuters
·
Apr 25

China National Investment & Guaranty Refutes Collaboration Claims with NAMS on Investment Products

Deep News
·
Apr 23

NewAmsterdam Pharma announces annual shareholder meeting

Reuters
·
Apr 20

A Look At NewAmsterdam Pharma (NAMS) Valuation After Positive Obicetrapib Trial Sentiment And ACC.26 Data Presentations

Simply Wall St.
·
Apr 05

NewAmsterdam Pharma grants 15,000 inducement options under Nasdaq Rule 5635(c)(4)

Reuters
·
Apr 03

Will ACC.26 Obicetrapib Data on Kidney, Safety and Lipids Change NewAmsterdam Pharma's (NAMS) Narrative?

Simply Wall St.
·
Mar 30

NewAmsterdam Pharma published BROADWAY trial presentation; pooled BROADWAY and BROOKLYN analysis shows slower annualized eGFR decline on obicetrapib vs placebo

Reuters
·
Mar 26

NewAmsterdam Pharma publishes pooled Phase III safety presentation on obicetrapib; TEAEs fall to 60.2% from 62.0%

Reuters
·
Mar 26

NewAmsterdam Pharma posts BROADWAY trial presentation on obicetrapib kidney outcomes

Reuters
·
Mar 25

NewAmsterdam Pharma to present BROADWAY trial results on obicetrapib at ACC.26

Reuters
·
Mar 23

Truist Initiates NewAmsterdam Pharma at Buy With $57 Price Target

MT Newswires Live
·
Mar 19

NewAmsterdam Pharma initiated with a Buy at Truist

TIPRANKS
·
Mar 19

NewAmsterdam Pharma Reports Nasdaq-Rule Inducement Grants Under 2024 Inducement Plan

Reuters
·
Mar 07